FindTrial
Sign In

Pharmacokinetic Analysis of Nicotinamide Riboside

Status
Completed
Phases
Early Phase 1
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02300740
Enrollment
12
Registered
2014-11-25
Start date
2014-12-31
Completion date
Unknown
Last updated
2015-02-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy Participants

Brief summary

Nicotinamide riboside is a newly discovered vitamin B3. The pharmacokinetics in humans is so far not analyzed.

Interventions

DIETARY_SUPPLEMENTNicotinamide riboside

NIAGEN, ChromaDex

Sponsors

University of Copenhagen
CollaboratorOTHER
Aarhus University Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
MALE
Age
18 Years to 30 Years
Healthy volunteers
Yes

Inclusion criteria

* BMI 18-25, healthy, male,

Exclusion criteria

* liver or kidney diseases, other diseases

Design outcomes

Primary

MeasureTime frame
Serum nicotinamide riboside8 hours, blood samples every 15 min

Secondary

MeasureTime frame
serum concentrations of metabolites of nicotinamide riboside8 hour, blood samples every 15 min
area under the curve for serum nicotinamide riboside8 hours, blood samples every 15 min
calculation of halftime of serum nicotinamide riboside8 hours, blood samples every 15 min
calculation of C-max of serum nicotinamide riboside8 hours, blood samples every 15 min
calculation of t-max of serum nicotinamide riboside8 hours, blood samples every 15 min

Countries

Denmark

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026